# Alnylam Pharmaceuticals, Inc. (ALNY) — Financial Analysis and SEC Results

> Official primary source: SEC EDGAR (CIK: 1178670). Listed on Nasdaq.
> Sector: Salud · Industry: Pharmaceutical Preparations
> Canonical URL: https://cifraresearch.com/en/empresa/ALNY

## Business Profile

Profile and analysis of Alnylam Pharmaceuticals, Inc. in the health care sector: 10-Q and 10-K results, quote and AI analysis of sales, free cash flow and capital allocation.

## Executive Financial Summary

In its most recent fiscal year (2025), Alnylam Pharmaceuticals, Inc. reported sales of 3714 M$, net income of 314 M$ and free cash flow (FCF) of 465 M$ (13% FCF margin) (diluted earnings per share of 2,33 $).

## Annual Financial Results (Recent Fiscal Years)

| Fiscal Year | Revenue | Operating Income | Net Income | Free Cash Flow (FCF) | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | 3714 M$ | 502 M$ | 314 M$ | 465 M$ | 2,33 $ |
| 2024 | 2248 M$ | -177 M$ | -278 M$ | -43 M$ | -2,18 $ |
| 2023 | 1828 M$ | -282 M$ | -440 M$ | 42 M$ | -3,52 $ |
| 2022 | 1037 M$ | -785 M$ | -1131 M$ | -613 M$ | -9,30 $ |
| 2021 | 844 M$ | -709 M$ | -853 M$ | -718 M$ | -7,20 $ |

## 10-Q and 10-K Filings Submitted to the SEC

- [10-Q (Q3 2026)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm) — Filed on 2026-10-29
- [10-Q (Q2 2026)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) — Filed on 2026-07-30
- [10-Q (Q1 2026)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm) — Filed on 2026-04-30
- [10-K (FY 2025)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm) — Filed on 2026-02-12
- [10-Q (Q3 2025)](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm) — Filed on 2025-10-30
- [10-Q (Q2 2025)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/alny-20250630.htm) — Filed on 2025-07-31
- [10-Q (Q1 2025)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm) — Filed on 2025-05-01
- [10-K (FY 2024)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm) — Filed on 2025-02-13

## Reports Analyzed with AI on Cifra

- [Report 10-K Resultados del ejercicio 2025 — ALNY](https://cifraresearch.com/informe/ALNY/2025-10K) ([Markdown](https://cifraresearch.com/informe/ALNY/2025-10K.md))
- [Report 10-Q 2026 Q3 results — ALNY](https://cifraresearch.com/informe/ALNY/2026-Q3) ([Markdown](https://cifraresearch.com/informe/ALNY/2026-Q3.md))

## Frequently Asked Questions

### What sector and industry does Alnylam Pharmaceuticals, Inc. operate in?
Alnylam Pharmaceuticals, Inc. (ALNY) is listed on Nasdaq and operates in the Pharmaceutical Preparations industry (consumer defensive sector in SEC EDGAR).

### Where can I consult official filings for ALNY?
In the official SEC EDGAR system under CIK 1178670 (https://www.sec.gov/edgar) or on Cifra's interactive company page (https://cifraresearch.com/en/empresa/ALNY).

## Citation and Attribution

Data extracted from SEC EDGAR. Analysis structured by Cifra (https://cifraresearch.com). For informational purposes only.